OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Internal Medicine is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
COVID‐19 diagnosis and management: a comprehensive review	829
Clinical and epidemiological characteristics of 1420 European patients with mild‐to‐moderate coronavirus disease 2019	556
Senolytic drugs: from discovery to translation	510
Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID‐19 patients in Michigan, United States	248
Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19)	224
The Mediterranean diet and health: a comprehensive overview	215
Perspective: Vitamin D deficiency and COVID‐19 severity – plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis	163
Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients	154
Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016	143
Cytokine storm syndrome in coronavirus disease 2019: A narrative review	136
Short‐term neuropsychiatric outcomes and quality of life in COVID‐19 survivors	134
Systemic amyloidosis from A (AA) to T (ATTR): a review	133
Ambient air pollution and cardiovascular diseases: An umbrella review of systematic reviews and meta‐analyses	127
The impact of novel coronavirus COVID‐19 on noncommunicable disease patients and health systems: a review	118
COVID‐19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?	111
Homocysteine – from disease biomarker to disease prevention	104
Contribution of remnant cholesterol to cardiovascular risk	95
Breathing, speaking, coughing or sneezing: What drives transmission of SARS‐CoV‐2?	94
Immunity to SARS‐CoV‐2 induced by infection or vaccination	91
Insights into disparities observed with COVID‐19	85
Nanotechnology for modern medicine: next step towards clinical translation	84
Advances in the Omicron variant development	81
Mitochondrial disease in children	80
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis	73
Direct oral anticoagulant use and risk of severe COVID‐19	72

Elevated markers of gut leakage and inflammasome activation in COVID‐19 patients with cardiac involvement	71
How can dementia and disability be prevented in older adults: where are we today and where are we going?	67
Racial disparities in COVID‐19 deaths reveal harsh truths about structural inequality in America	60
Patients with Lemierre syndrome have a high risk of new thromboembolic complications, clinical sequelae and death: an analysis of 712 cases	60
Cancer survival statistics for patients and healthcare professionals – a tutorial of real‐world data analysis	60
Current treatment of non‐alcoholic fatty liver disease	59
Association of mitochondrial DNA copy number with metabolic syndrome and type 2 diabetes in 14 176 individuals	59
Targeting Kras^g12c‐mutant cancer with a mutation‐specific inhibitor	54
High frequency of antiphospholipid antibodies in critically ill COVID‐19 patients: a link with hypercoagulability?	54
Airway organoids as models of human disease	53
Arterial stiffness in acute COVID‐19 and potential associations with clinical outcome	53
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease	51
Epigenetic regulation of insulin action and secretion – role in the pathogenesis of type 2 diabetes	50
Genetics of coronary artery disease in the post‐GWAS era	48
Strategies for fighting mitochondrial diseases	47
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies	45
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials	44
Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor?	44
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis	43
Hypocretins (orexins): The ultimate translational neuropeptides	43
Assessment of thirty‐day readmission rate, timing, causes and predictors after hospitalization with COVID‐19	43
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID‐19: a retrospective cohort study	43